Tufts Center for the Study of Drug Development

Tufts CSDD's September 2024 Insider eNewsletter is here 🍁 Some highlights from this month's issue: 📖   Launch of Study Mapping & Quantifying Effectiveness of Centralized Recruitment Methods  🤝  Upcoming In-Person Roundtable On Optimizing the Regulatory Submission Preparation Process 🎤   Tufts CSDD Data Scientist Abigail Dirks, MS Talks RBQM Adoption with Pharma Focus Asia Click below to read this month's issue and subscribe to get future issues delivered directly to your inbox: https://lnkd.in/eWY5bnhn

📣 Now Available! 📣 Tufts CSDD September/October Impact Report: “Participation Burden for Patients in Clinical Trials is Rising, Especially in Non-Oncology Studies” This latest issue presents the results of Tufts CSDD's groundbreaking work on assessing patient participation burden in clinical trials. Conducted in collaboration with 14 pharmaceutical companies, the results characterize factors contributing to rising levels of participation burden and identify opportunities to reduce this burden and optimize protocol designs. To purchase the issue or an annual subscription, visit https://bit.ly/3xEW55G. Multi-reader subscriptions are available at discounted rates. To learn more, please get in touch with [email protected]. #ParticipationBurden #ImpactReport #NewResearch

Happy Labor Day from Tufts CSDD! 🌟 🇺🇸In honor of this day dedicated to the hard work and dedication of our team and all workers, our center will be closed today, Monday, September 2nd. Wishing you all a safe and restful holiday!

In this episode, the third and final conversation of our mini-series on diversity in clinical trials, Lori Ellis (Katz) and guests Otis Johnson, PhD, MPA of Trial Equity, Pamela Tenaerts, MD, MBA of Medable, Inc, Christopher Escobedo Hart of Foley Hoag LLP, Patrick Floody of Regeneron, and Ken Getz of Tufts Center for the Study of Drug Development discuss framing strategies designed to protect DEI initiatives from legal challenges. https://hubs.li/Q02N1q6Q0 #pharma #podcast #biospace

Tufts CSDD is thrilled to announce our new research study exploring global investigative sites, innovative clinical trial models, and how the site landscape is evolving. We are looking to engage with pharma, biotech, and CRO organizations to participate in this new study. For more study details, contact Joan Chambers at [email protected] #StudyLaunch #GlobalSiteLandscape

New Tufts CSDD Study on Optimizing the Regulatory Submission Process The Tufts Center for the Study of Drug Development, Tufts University School of Medicine, is conducting a new study looking at trends, inefficiencies, and opportunities to optimize, the regulatory submission process. As part of this research we’re conducting a global survey among clinical research and regulatory professionals. Please take a moment to share your experience. As a thank you for your participation, we’ll send you a summary of the study findings, their implications and insights. Click here to begin the confidential survey: https://lnkd.in/e8YCVbyR

In the 1st year, Tufts CSDD's PACT Consortium has made significant progress. The Consortium is capturing real-use data on virtual and remote solutions supporting clinical trials. One finding, 'Companies are using on average 4 DCT Solutions per clinical trial, most often in support of study visit activity.' Become involved with this exciting initiative and the evolving clinical trial landscape. Become a member of the PACT Consortium today. Contact Joan Chambers at [email protected] 

Join Tufts CSDD's Circle of Supporters and play a pivotal role in advancing drug development research. Your collaboration fuels our mission to provide unparalleled insights into the complexities of drug innovation. Become a member today and gain exclusive access to our Research Pipeline and Priorities. Visit https://lnkd.in/ecU4iKrP or connect with Joan Chambers, [email protected] for more details and membership benefits.

The Tufts CSDD and DiMe research project revealed that developer costs to create a digital endpoint far exceed sponsor implementation and validation costs. The May/June 2024 Tufts CSDD Impact Report highlights that the mean reported cost for developers to create a digital endpoint is $21 million, more than 6 times higher than that for sponsors to implement and validate a digital endpoint. Additionally, the range of sponsor costs to implement and validate a digital endpoint is less than $500,000 to more than $15 million, with a mean reported cost of $3.4 million. More insights and reported findings are in the Tufts CSDD Impact Report. To purchase your copy or to subscribe annually, visit https://lnkd.in/dSYX898E or contact Joan Chambers at [email protected] Single and Multi-reader subscriptions are available. #DigitalEndpoints #DeveloperCosts

Exciting News! Tufts CSDD is launching a new research study exploring global investigative sites and innovative clinical trial models. Interested in learning more and participating? For details, connect with Joan Chambers at [email protected]. #GlobalSiteSurvey #ClinicalTrialResearch #TuftsCSDD